Cervical cancer screening company, TruScreen, has reported a smaller annual loss than last year, as it invests to meet demand from new markets.
The firm reported a loss of $692,000 in the 12 months to March, compared to a loss of $1.58 million the previous period.
Revenue was ahead of forecast at $2.2 million.
Its chief executive, Martin Dillon, said China, which represented about two thirds of global sales, was a focus.
He said getting regulatory approval in some markets had taken longer than expected.
But Mr Dillon said the firm was confident of better results in the current year.